_×
  0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Recombinant Protein > Human Cell Expressed > FCAR / CD89 Protein (His Tag)

FCAR / CD89 Protein (His Tag) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
10414-H08H
  YES          

Protein Production & Purification Service

Fc Fragment of IgA Protein Datasheet

 

CD89 / FCAR Protein Price Information

CD89 / FCAR Protein Product Information

CD89 Synonym: FCAR,XXbac-BPG230H20.5, CD89
Protein Construction: A DNA sequence encoding the pro form of human FCAR extracellular domain (NP_001991.1) (Met 1- Asn 227 ) was expressed with a C-terminal polyhistidine tag.
Source: Human
Expression Host: Human Cells

CD89 / FCAR Protein QC Testing

Purity: > 97%, as determined by SDS-PAGE SDS-PAGE:
SDS-PAGE

Bio-activity:

Measured by its ability to bind human IgA in functional Elisa.
Endotoxin: < 1.0 EU per 1μg of the protein as determined by the LAL method.
Stability: Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal: Gln 22
Molecular Mass: The secreted recombinant human CD89 is a monomeric protein consisting of 217 amino acids and predicts a molecular mass of 25 kDa. The apparent molecular mass of rhCD89 is approximately 45-50 kDa in SDS-PAGE under reducing conditions.
Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.

CD89 / FCAR Protein Usage Guide

Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage and usage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD89 / FCAR Protein Related Products & Topics

Related Areas:

Immunology>>Cluster of Differentiation>>Granulocyte CD Antigen>>Eosinophils / Neutrophils>>CD89/ FCAR

Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Other>>CD89/ FCAR

Immunology>>Fc Receptor>>CD89/ FCAR

Proteins:

Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
CD89/FCAR Human CD89/FCAR Protein, Recombinant 10414-H08H
CD89/FCAR Rat CD89/FCAR Protein, Recombinant 80014-R08H

Antibodies:

Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human
CD89/FCAR
ELISA Mouse Monoclonal Antibody 10414-MM02
Human
CD89/FCAR
WB, ELISA CD89/FCAR Antibody, Rabbit MAb 10414-R006
Human
CD89/FCAR
WB, ELISA Rabbit Polyclonal Antibody 10414-RP01
Human
CD89/FCAR
WB, ELISA Rabbit Polyclonal Antibody (Antigen Affinity Purified) 10414-RP02

CD89 / FCAR Protein Description

FCAR, also called FcαRI or CD89, is a type I  transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the surface of myeloid lineage cells such as neutrophils, monocytes, macrophages, and eosinophils, especially phagocytes located in mucosal areas. Upon ligand IgA binding, FcαRI associates with the FcR γ signaling molecule bearing the immunoreceptor tyrosine-based activation motif (ITAM) through a unique charge-based mechanism and triggers multiple cell-mediated immune responses. It has been reported that Fc RI is a dual-function receptor that can mediate both inflammatory and anti-inflammatory responses depending on the type of interaction with its ligand. Sustained aggregation of FCAR results in activation of target-cell functions such as antigen presentation and cytokine release. In contrast, Monomeric targeting with serum IgA or with a variety of anti-FcαRI Fab fragments triggers an inhibitory response and additionally induces apoptosis. FcαRI thus play an fundamental role in preventing tumor development and growth, as well as in controlling inflammation.

References

  1. Maliszewski, C.R. et al., 1990, J. Exp. Med. 172: 1665-1672.
  2. Launay, P. et al., 1999, J. Biol. Chem. 274: 7216-7225.
  3. Monteiro, R.C. et al., 2003, Annu. Rev. Immunol. 21: 177-204.
  4. Otten, M.A. et al., 2005, J. Immunol. 174: 5472-5480.
  5. Pasquier, B. et al., 2005, Immunity. 22:31-42.
  6. Kanamaru, Y. et al., 2007, Blood. 109: 203-211.
 

 

 

CD89 (FCAR) related areas, pathways, and other information